Table 2.

Baseline (within 3 months) CMR and clinical variables comparing individuals with and without serious adverse outcomes. Variables presented as median (IQR). LVESVi: indexed left ventricular end-systolic volume, LVEDVi: indexed left ventricular end-diastolic volume, LVSVi: left ventricular stroke volume index, LVMI: left ventricular mass index, ECV: extracellular volume, LV GLS: left ventricular global longitudinal strain, BMI: body mass index. *Mean T1 and T2 times only reported for UPMC participants (T1 normative range: 960-1080 msec, T2 normative range < 45 msec).

CMR variables	No adverse outcomes (n = 45)	Adverse outcomes (n = 6)	P-value
Left ventricular variables
LVESVi (ml/m2)	67.4 (49.5, 99.4)	145.0 (44.4, 162.0)	0.07
LVEDVi (ml/m2)	101.6 (81.3, 122.7)	164.2 (59.4, 191.0)	0.22
LVMI (g/m2)	62.0 (49.0, 72.0)	68.5 (54.0, 70.0)	0.51
Concentricity (g/ml)	0.57 (0.48, 0.65)	0.49 (0.42, 0.59)	0.34
LV stroke volume (ml)	58.4 (39.4, 74.6)	32.1 (29.2, 34.2)	0.005
LV SVi (ml/m2)	33.3 (20.9, 42.0)	17.5 (15.0, 20.2)	0.007
Heart rate (bpm)	79 (67, 96)	110 (98, 122)	0.001
Cardiac output (L/min)	4.6 (3.2, 5.4)	3.6 (3.4, 4.3)	0.32
LVEF (%) (by CMR)	37.3 (25.6, 49.1)	15.0 (15.0,17.0)	0.001
Valvular abnormalities
Mitral regurgitation
Mild/moderate/severe	12/4/4 (27/9/9 %)	1/1/0 (25/25/0 %)	0.69
Right ventricular variables
Systolic function
Mild/moderate/severe	2/2/5 (4/4/11 %)	2/2/1 (33/33/17 %)	0.002
Dilation
Mild/moderate/severe	4/1/1 (9/2/2 %)	3/1/0 (60/20/0 %)	0.005
Parametric mapping
Mean T1 time (msec)*	1116.8 (1053.5, 1151,0) (n = 14)	1108 (994.5, 1223.0) (n = 2)	1.0
Mean T2 time (msec)*	55.1 (52.9, 60.2) (n = 14)	60.3 (50.9, 82.0) (n = 2)	0.55
Post-processing
Mean ECV (%)	28.2 (24.7, 33.8) (n = 13)	43.6 (42.4,44.8) (n = 2)	0.02
Peak LV GLS (%)	−10.0 (−12.6, −6.9)	−4.1 (−5.9, −3.9)	0.002
Obesity markers
Epicardial fat volume (ml)	61.2 (45.3, 72.8)	64.2 (62.1, 66.2)	0.64